Klaus R. Dr Veitinger, Director at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 391 shares at $272.79 ($109K) on 2015-05-11, disclosed to the SEC on 2015-05-13.
Scheduled sale ($109k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $272.79 | 158 | $43K | 39.5% |
| 2 | $283.33 | 233 | $66K | 60.5% |
| Total | $279.07 avg | 391 | $109K | 100% |
| Filing → |
| TCDA | SELL | 2019-09-30 | $132K | — | Filing → |
| TCDA | SELL | 2019-08-28 | $139K | — | Filing → |
| TCDA | SELL | 2019-07-29 | $133K | — | Filing → |